OraSure Technologies Company Profile (NASDAQ:OSUR)

OraSure Technologies trades on the NASDAQ under the ticker symbol "OSUR."

OraSure Technologies, Inc. (NASDAQ:OSUR) issued its quarterly earnings results on Wednesday, August, 2nd. The company reported $0.09 EPS for the quarter, beating analysts' consensus estimates of $0.07 by $0.02. The business had revenue of $40.18 million for the quarter, compared to analysts' expectations of $36.54 million. OraSure Technologies had a net margin of 22.29% and a return on equity of 15.64%. The business's quarterly revenue was up 28.1% on a year-over-year basis. During the same period last year, the business earned $0.07 earnings per share. View OraSure Technologies' Earnings History.

OraSure Technologies is scheduled to release their next quarterly earnings announcement on Tuesday, October, 31st 2017. View Earnings Estimates for OraSure Technologies.

OraSure Technologies updated its third quarter earnings guidance on Wednesday, August, 2nd. The company provided earnings per share guidance of $0.09-0.10 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $0.08. The company issued revenue guidance of $40.5-41.5 million, compared to the consensus revenue estimate of $37.64 million.

6 brokers have issued 12-month target prices for OraSure Technologies' shares. Their predictions range from $8.00 to $22.00. On average, they expect OraSure Technologies' stock price to reach $15.04 in the next twelve months. View Analyst Ratings for OraSure Technologies.

Here are some recent quotes from research analysts about OraSure Technologies stock:

• 1. According to Zacks Investment Research, "OraSure Technologies, Inc. is the market leader for oral fluid diagnostics. The Company develops, manufactures, and markets medical devices and diagnostic products for use by insurance companies, public health agencies, clinical laboratories, physicians' offices, and workplace sites. " (5/6/2017)
• 2. BTIG Research analysts commented, "While we do not see any meaningful negatives for OSUR shares and see room for slight appreciation over time, we feel a lot of good news and higher expectations are now built into shares and would prefer a better entry point," analyst Karen Koski wrote in a note.Related Link: How The Zika Virus Spread While Congress With Out On RecessHowever, Koski acknowledged the company's new $18 million HCV test contract, improving operating margins, and a solid balance sheet. But, the analyst prefers to stay on sidelines due to the OraSure's "lumpy sales."Though OSUR has met or exceeded its sales guidance every quarter for the past several years, investors care most about HCV testing and DNAG sales, which can be lumpy," (9/19/2016)

Some companies that are related to OraSure Technologies include Haemonetics Corporation (HAE), Halyard Health (HYH), Inogen (INGN), MiMedx Group (MDXG), CONMED Corporation (CNMD), K2M Group Holdings (KTWO), Cardiovascular Systems (CSII), Asante Solutions (PUMP), Intersect ENT (XENT), Orthofix International N.V. (OFIX), AtriCure (ATRC), CryoLife (CRY), Meridian Bioscience (VIVO), Landauer (LDR), Consort Medical plc (CSRT), Antares Pharma (ATRS), STAAR Surgical Company (STAA) and Invacare Corporation (IVC).

OraSure Technologies' management team includes the folowing people:

• Stephen S. Tang Ph.D., Chairman of the Board
• Douglas A. Michels, President, Chief Executive Officer, Director
• Ronald H. Spair, Chief Financial Officer, Chief Operating Officer, Director
• Anthony II Zezzo II, Executive Vice President - Marketing and Sales
• Mark L. Kuna, Senior Vice President - Finance, Controller, Assistant Secretary
• Michael Reed Ph.D., Senior Vice President - Research and Development, Chief Scientific Officer
• Jack E. Jerrett, Senior Vice President, General Counsel, Secretary
• Mara Glickman Aspinall, Director
• Eamonn P. Hobbs, Director
• Michael Celano, Independent Director

OraSure Technologies' stock is owned by a number of of retail and institutional investors. Top institutional investors include BlackRock Inc. (12.61%), Vanguard Group Inc. (9.15%), Renaissance Technologies LLC (8.73%), Dimensional Fund Advisors LP (5.23%), Daruma Capital Management LLC (4.75%) and Acadian Asset Management LLC (3.20%). Company insiders that own OraSure Technologies stock include Anthony Zezzo II, Charles W Patrick, Douglas A Michels, Jack E Jerrett, Mark L Kuna, Michael Celano, Ronald H Spair, Ronny B Lancaster and Stephen S Phd Tang. View Institutional Ownership Trends for OraSure Technologies.

OraSure Technologies' stock was sold by a variety of institutional investors in the last quarter, including Wells Fargo & Company MN, JPMorgan Chase & Co., Thrivent Financial For Lutherans, BlackRock Inc., Cornerstone Capital Management Holdings LLC., Prudential Financial Inc., Alliancebernstein L.P. and Globeflex Capital L P. Company insiders that have sold OraSure Technologies stock in the last year include Anthony Zezzo II, Charles W Patrick, Douglas A Michels, Jack E Jerrett, Mark L Kuna, Michael Celano, Ronald H Spair, Ronny B Lancaster and Stephen S Phd Tang. View Insider Buying and Selling for OraSure Technologies.

OraSure Technologies' stock was acquired by a variety of institutional investors in the last quarter, including Daruma Capital Management LLC, Vanguard Group Inc., Acadian Asset Management LLC, Columbus Circle Investors, Public Employees Retirement System of Ohio, Russell Investments Group Ltd., Intrinsic Edge Capital Management LLC and Federated Investors Inc. PA. View Insider Buying and Selling for OraSure Technologies.

Shares of OraSure Technologies can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of OraSure Technologies stock can currently be purchased for approximately $19.97.